2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Folate Receptor (FR)

Folate Receptor (FR)

Folate Receptor (FR)

Folate receptor (FR) is a class of cysteine-rich glycosylphosphatidylinositol-coupled protein that can mediate folate transport from outside to inside cells, and is divided into FR-α, FR-β, and FR-γ Subtypes. FR-α is expressed in renal proximal tubules and in various solid epithelial neoplasms (ovary, endometrium, brain, lung, and renal cancers). FR-β is expressed in normal hematopoietic tissue, activated macrophages, and hematogenous malignancies. Folate receptor can be used for the early diagnosis and study of tumors[1]sup>[2].

Folate Receptor (FR) Isoform Specific Products:

Folate Receptor (FR) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13615A
    EC-17 disodium salt
    EC-17 disodium salt is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The EC-17 maximum excitation and emission wavelengths are 490 nm and 520 nm, respectively.
    EC-17 disodium salt
  • HY-W440888
    DSPE-PEG2000-Folate
    DSPE-PEG2000-Folate (DSPE-PEG2000 Folate) is a folate-containing PEG derivative. DSPE-PEG2000-Folate possesses targeting activity and binds to folate receptors in cancer cells. DSPE-PEG2000-Folate can be post-inserted into preformed liposomal bilayers to prepare folate-targeted liposomal formulations. DSPE-PEG2000-Folate forms micelles/lipid bilayers and can be used in studies of targeted drug delivery systems[2].
    DSPE-PEG2000-Folate
  • HY-13615
    Folate-FITC
    Folate-FITC (EC-17) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The Folate-FITC maximum excitation and emission wavelengths are 490 nm and 520 nm, respectively.
    Folate-FITC
  • HY-P10762
    Ricorfotide vedotin
    		Ligand 98.45%
    Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma).
    Ricorfotide vedotin
  • HY-P11024
    NVP-EVS459
    		98.11%
    NVP-EVS459 is a Folate Receptor (FR)-targeting radioconjugate. NVP-EVS459 labeled with 177Lu can be used for tumor diagnosis and research.
    NVP-EVS459
  • HY-P992112
    Eliroptamig
    		Inhibitor
    Eliroptamig is a multispecific antibody targeting albumin, folate receptor α (FOLR1) and cluster of differentiation 3 (CD3). Eliroptamig extends its half-life by binding to albumin, while targeting FOLR1 on tumor cells and activating T cells to achieve precise tumor killing.
    Eliroptamig
  • HY-185427
    Opugotamig olatansine
    		Modulator
    Opugotamig olatansine (IMGN151) is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC). Opugotamig olatansine comprises antibody Opugotamig (HY-P990935) and linker-payload NMS-P945 (HY-185569). Opugotamig olatansine binds to two independent epitopes of FRα and promotes antibody binding, internalization, and processing. Opugotamig olatansine can be used for the research of FRα-positive ovarian cancer.
    Opugotamig olatansine
  • HY-P992510
    Sofetabart
    		Inhibitor
    Sofetabart (LY-4170156 Antibody) is an Fc-silenced, humanized IgG1 antibody targeting FRα, a composition of antibody drug conjugate (ADC) LY-4170156. Sofetabart can be used for the research of Platinum-resistant ovarian cancer and platinum-sensitive ovarian cancer.
    Sofetabart
  • HY-W1123936B
    DBCO-PEG1000-FA
    		Ligand
    DBCO-PEG1000-FA (DBCO-PEG1000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
    DBCO-PEG1000-FA
  • HY-P991695
    Lazatatug
    		Inhibitor
    Lazatatug is an anti-FOLR1 IgEκ type humanized antibody with antineoplastic activity.
    Lazatatug
  • HY-P10740
    CBP-1018
    		Ligand 99.21%
    CBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer.
    CBP-1018
  • HY-W1123936D
    DBCO-PEG3400-FA
    		Ligand
    DBCO-PEG-FA (DBCO-PEG-Folate) (MW 3400) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
    DBCO-PEG3400-FA
  • HY-W1123936H
    DBCO-PEG10000-FA
    		Ligand
    DBCO-PEG10000-FA (DBCO-PEG10000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
    DBCO-PEG10000-FA
  • HY-128937
    EC1454
    EC1454 is a peptide compound with anticancer activity that targets folate receptor-expressing cancers. EC1454 is a folate-tubulysin conjugate that can be used to prepare drug delivery conjugates for targeted therapy.
    EC1454
  • HY-16181
    EC-0225
    		Inhibitor
    EC-0225, a folate conjugate of two agents- one a potent microtubule inhibiting agent, and the second a DNA alkylating agent. EC-0225 inhibits the growth of folate receptor (FR)-positive KB cells with an IC50 of ~1 nM. EC-0225 can be selectively delivered to advanced FR-positive tumors without causing overt toxicity, such as lung carcinoma.
    EC-0225
  • HY-180557
    4A-BFA-11
    4A-BFA-11 is a folate-targeted PEG-MMAE conjugate that exhibits specific binding affinity for the folate receptor α (FR-α) (KD = 106.7 nM). 4A-BFA-11 achieves tumor enrichment by combining PEG-mediated long circulation (EPR effect) and folate receptor targeting. 4A-BFA-11 undergoes enzymatic cleavage at the tumor site to release the active payload, enabling precise action. 4A-BFA-11 sefficiently carries, targets, and controls the release of MMAE in tumor tissues in a HeLa mouse model. 4A-BFA-11 can be used for cervical cancer, ovarian cancer, and lung cancer research.
    4A-BFA-11
  • HY-P2631
    EC119
    EC119 consists of Pteroic acid-gGlu-Asp-Arg-Asp-Asp-Cys, which is the folate–peptide moiety found within both the EC140 and EC145 structures.
    EC119
  • HY-P992124
    Onvontatug
    		Inhibitor
    Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer.
    Onvontatug
  • HY-W1123936C
    DBCO-PEG2000-FA
    		Ligand
    DBCO-PEG2000-FA (DBCO-PEG2000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
    DBCO-PEG2000-FA
  • HY-127118A
    Pteropterin monohydrate
    		Activator
    Pteropterin (Pteroyltriglutamic) monohydrate is an active form of folate. Pteropterin monohydrate shows inhibiting effect on tumor growth and has broad anticancer activity.
    Pteropterin monohydrate
Folate Receptor (FR) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.